Table 2: Follow up after rituximab therapy.
Patient number | RTX total dose per course (mg) | CD19 count after RTX (%) | Growth velocity (cm/year) | eGFR (ml/min/1.73 m2) | Albumin (g/dL) | Number of relapses | Time to first relapse (days) | ||||
0 | 12m | 0 | 12m | 0 | 12m | -12m | 12m | ||||
1 | 1000 | 0 | 2.5 | 3.0 | 100 | 106 | 45 | / | 4 | 0 | 426 |
2 | 2000 | 0.3 | 0.0 | 0.0 | 124 | 132 | 38 | 42 | 4 | 1 | 213 |
3 | 1000 | 0.1 | 0.0 | 0.0 | 84 | 89 | 27 | 34 | 1 | 1 | 234 |
4 | 1000 | 0 | 0.0 | 0.0 | 46 | 59 | 33 | 20 | 4 | 2 | 266 |
5 | 1000 | 0 | 2.9 | 1.3 | 94 | 105 | 39 | 43 | 3 | 0 | 531 |
6 | 1000 | 0 | 3.0 | 3.7 | 155 | 133 | 25 | 28 | 5 | 1 | 322 |
7 | 1000 | 0.2 | 3.0 | 4.3 | 108 | 112 | 24 | 44 | 7 | 3 | 158 |
8 | 1000 | 0.2 | 5.6 | 12.4 | 97 | 124 | 42 | 33 | 2 | 1 | 349 |
9 | 1000 | 0.2 | 2.0 | 2.7 | 118 | 95 | 30 | 45 | 2 | 0 | 377 |
10 | 1000 | 0.2 | 4.1 | 4.9 | 97 | 112 | 39 | 38 | 2 | 0 | 409 |
11 | 1000 | 0.3 | 2.2 | 4.8 | 92 | 87 | 26 | 44 | 5 | 0 | 574 |
RTX = Rituximab; -12m = 1 year before rituximab therapy; 0 = At time of rituximab therapy; 12m = 1 year after rituximab therapy.